Astralis, Ltd.

Phase II results of psoriasis drug presented at dermatology meeting

Published in Pharma Investments, Ventures and Law Weekly, June 12th, 2005

Astralis, Ltd., (ASTR) announced that the results of its 120-patient, 11-site, multidose phase II clinical trial of Psoraxine, its product for the treatment of psoriasis, was presented at the Society of Investigational Dermatology meeting in St. Louis, Missouri, on May 6, 2005.

The report authored by James Kreuger, professor and medical director of Investigative Dermatology at Rockefeller University, and Bruce Miller, MD at Oregon Medical Research Center, presents both PASI (Psoriasis Area Severity Index) and patient biopsy results, respectively the primary and secondary endpoints of the trial.

Although the six injection, 20 week trial of Psoraxine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly

Source: Pharma Investments, Ventures and Law Weekly (2005-06-12)

More Articles from Pharma Investments, Ventures and Law Weekly

A.P. Pharma, Inc.
Pharmaceutical firm reports loss of $0.05 per share, clinical trial update
AC Immune
Swiss biotech company raises CHF 21M in private financing
Abbott
Sales increase 14% for pharmaceutical company
Acadia Pharmaceuticals, Inc.
Biopharmaceutical company reports first quarter loss of $5.6M
Access Pharmaceuticals, Inc.
Pharmaceutical firm records loss of $0.16 per share
Advancis Pharmaceutical Corporation
Private placement of common equity closed by pharma firm
More from this issue of Pharma Investments, Ventures and Law Weekly

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry